Lenvatinib Exhibits Potent Anti-tumor Activity and Favorable Safety Profile in a Colorectal Cancer Xenograft Model
Lenvatinib exhibits potent anti-CRC activity with minimal systemic toxicity. Its therapeutic effects are mediated through ERK pathway inactivation, suppression of anti-apoptotic proteins, and induction of caspase-dependent apoptosis.
Authors
- Fei‐Ting Hsu (ORCID: https://orcid.org/0000-0002-2153-340X)
- Chen-Yu Kuo
- Ching Ming Chang
- Tsai-Lan Liao
- Jing-Jim Ou
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Central University (TW)
- National Yang Ming University Hospital (TW)
- Chang Bing Show Chwan Memorial Hospital (TW)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-01-30
- DOI
- https://doi.org/10.21873/anticanres.17988
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00